Yusuke Nakamura to Hepatitis C
This is a "connection" page, showing publications Yusuke Nakamura has written about Hepatitis C.
Connection Strength
0.559
-
Identification of a functional variant in the MICA promoter which regulates MICA expression and increases HCV-related hepatocellular carcinoma risk. PLoS One. 2013; 8(4):e61279.
Score: 0.095
-
A genome-wide association study of HCV-induced liver cirrhosis in the Japanese population identifies novel susceptibility loci at the MHC region. J Hepatol. 2013 May; 58(5):875-82.
Score: 0.093
-
Amino acid substitution in HCV core/NS5A region and genetic variation near IL28B gene affect treatment efficacy to interferon plus ribavirin combination therapy. Intervirology. 2012; 55(3):231-41.
Score: 0.084
-
IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. J Infect Dis. 2011 Jul 01; 204(1):84-93.
Score: 0.084
-
A single nucleotide polymorphism in activated Cdc42 associated tyrosine kinase 1 influences the interferon therapy in hepatitis C patients. J Hepatol. 2011 Apr; 54(4):629-39.
Score: 0.080
-
ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy--a genome-wide study of Japanese HCV virus patients. Gastroenterology. 2010 Oct; 139(4):1190-7.
Score: 0.078
-
Amino acid substitution in HCV core region and genetic variation near the IL28B gene affect viral dynamics during telaprevir, peginterferon and ribavirin treatment. Intervirology. 2012; 55(6):417-25.
Score: 0.022
-
Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet. 2012 May 27; 44(7):760-4.
Score: 0.022